Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AbbVie, advice, Afrin, Agencia, agile, Akorn, alendronate, allergen, Allergenic, Alnylam, Amgen, amnestic, anniversary, API, aprepitant, Aquaflor, Arcoxia, Aspen, ASR, auction, Avelox, Banamine, Bank, Bedford, Ben, benzoate, bid, biosimilar, BMS, bolstering, bound, Brazilian, breadth, breakthrough, broadly, Byetta, Canan, capable, Caravello, Cerazette, Chilcott, Chinese, Clarinex, Claritin, Clostridium, Coccivac, cognitive, colorectal, Compact, Complimentary, concomitant, confident, confirmatory, Coppertone, Coricidin, cotransporter, coupled, creation, CRL, desloratadine, desogestrel, developmental, devoting, discrimination, discriminatory, disparate, Dulera, dust, ear, effectuate, EPO, ertapenem, ertugliflozin, Estrumate, etoricoxib, Eurofarma, Ezetrol, facilitate, Farma, Fast, fed, feed, fluroquinolone, follicular, follitropin, footprint, Forest, Fosamac, Fosavance, Francisco, Franklin, gastric, glargine, Glynn, Goldman, Grastek, HBP, HCl, HCV, heightened, hostile, house, Implanon, inconsistent, incorrect, Inegy, Interactive, intolerant, Invanz, ipilimumab, Jellema, Karachun, Kelli, kinase, Korea, lesser, Lotrimin, Love, lump, Marvelon, Maryland, mild, mobile, modality, Montana, moxifloxacin, multinational, Munter, Nacional, neck, Nobivac, nonproprietary, Nuflor, omarigliptin, Ono, Oxytrol, Paracox, parasiticide, perlmutter, philanthropic, platform, Pneumovax, policymaker, posaconazole, preempted, preemption, Primaxin, proactive, prodromal, proper, Proscar, Puregon, Ragwitek, Rebetol, recurrence, Remeron, repricing, Resflor, resignation, retaliation, retroactively, Revalor, revocation, revoke, Rita, rizatriptan, ROGER, Rosenberg, round, ruminant, salt, Samsung, San, Scheinberg, Sessner, sharpen, SICAD, Sirna, Slice, Spano, sponte, spun, St, staggered, sua, successor, sue, Supera, surrogate, suspension, Sweet, Sycrest, Taxpayer, Temodal, tildrakizumab, timeline, Timothy, Tinactin, toll, top, Track, triple, true, Trusopt, Unanski, unfiled, unrepatriated, vacate, vacated, valent, Varivax, verify, Victoza, Vigilancia, Warner, weekly, winding, Zegerid, Zilmax, Zocor, Zoely, Zuprevo
Removed:
air, alpha, anal, ANDA, andAquaflorantibiotic, andClarinex, andFosamax, andIntron, andPorcilisvaccine, andResearch, andVytorin, andZegerid, angiotensin, argument, ARIAD, asAeriusin, asEzetrol, asEzetroloutside, asFosamacin, asFosavancethroughout, asInegy, asInegyoutside, asNoncontrolling, asOther, asPuregon, assetsare, assetswere, atorvastatin, atrial, balancing, beende, body, butsua, captionIn, certainFosamaxproduct, cervical, commencing, commercializeSimponi, competitor, concerningVytorinand, Conservation, consolidatedIncome, constituted, consultation, conversion, convertible, Coppertonesun, CR, damage, diminution, disputed, dissolvable, downturn, dupont, dysplastic, enterprise, equipmentand, estrogen, factual, fibrillation, forCosoptwill, forMaxalt, forMaxaltwill, forSimponi, forSingulair, FosamaxLitigation, Frameworkissued, Fred, fromAOCI, gastrointestinal, genital, glaucoma, Glenmark, Greek, groundwater, halted, Hamni, Hassan, HDL, heard, hemorrhage, Impax, inAccrued, inAccumulated, inAOCIand, incidence, includeCozaarandHyzaar, incomein, inDeferred, India, inducing, inEquity, informed, inInternal, inNoncontrolling, inOCI, inOther, inProperty, inRestructuring, inRosenberg, interestsin, intoSaleswhen, intracranial, intraocular, isde, JanuviaandJanumetfor, KIM, laropiprant, liabilitieswere, licensor, mammalian, marketCozaarandHyzaar, men, metastatic, Mexico, minimisand, mTOR, municipal, nameSycrest, naturally, negligence, niacin, Nuflorantibiotic, nuisance, NuvaRingMDL, ocular, ofAccumulated, ofBridionwere, ofCozaar, ofCozaarand, ofEmend, ofFollistim, ofFosamax, ofFosamaxand, ofFosamaxandFosamax, ofGardasil, ofJanumet, ofJanuvia, ofMaxalt, ofNasonex, ofNuvaRing, ofOCI, ofOther, ofPneumovax, ofPrimaxin, ofPropecia, ofSimponi, ofSingulair, ofSingulairin, ofTemodar, ofVioxx, ofVytorin, ofVytorinandZetia, ofVytorinandZetiain, ofZetia, onPrimaxinhave, onVioxxby, page, parent, participated, peripheral, phased, productsper, prostaglandin, purportedly, rapamycin, receivableandAccrued, reducedIncome, regained, remeasure, retiree, retirement, revascularization, sarcoma, secondary, selective, Sliceparasiticide, soil, sponsored, sponteordered, Standardsapplicable, subsidy, sugar, surgical, tafluprost, taxesby, taxeswould, TheBolescase, theFosamaxproduct, theNuvaRing, theNuvaRingMDL, thevioxx, thevioxxlitigation, thevioxxproduct, theVytorin, thrombin, throughOther, toAggrastat, toOther, toSalesmay, toSimponi, toVioxx, toVioxxin, toVytorin, TRACER, treating, unamortized, updated, vernakalant, virtue, vulvar, withdraw, withdrewVioxx, withinOCI, withinRestructuring, working, write, XR
Filing tables
Filing exhibits
- 10-K Annual report
- 3.2 EX-3.2: By-laws of Merck & Co., Inc. (Eff Feb 25 2014)
- 12 EX-12: Computation of Ratio of Earnings to Fixed Charges
- 21 Ex 21: Subsidiaries
- 23 EX-23: Consent of Independent Registered Public Accounting Firm
- 24.1 EX-24.1: Power of Attorney
- 24.2 EX-24.2: Certification of Board Resolution
- 31.1 EX-31.1: CEO Certification
- 31.2 EX-31.2: CFO Certification
- 32.1 EX-32.1: CEO Certification
- 32.2 EX-32.2: CFO Certification
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 27, 2014 | /s/ Kenneth C. Frazier | |
Name: KENNETH C. FRAZIER | ||
Title: Chairman, President and Chief Executive Officer |